Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | August 31, 2026 | September 02, 2026 |
| PRECIGEN, INC.PGEN · Entity 4356 | Director | March 13, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,747 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 1,288 · Balance 36,747 F1: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.
PRECIGEN, INC.
Report date March 13, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,226,391 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Exercise / conversion · Acquired 71,839 · Balance 1,226,391 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Exercise / conversion · Disposed 71,839 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2: The RSUs vested in full on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2: The RSUs vested in full on March 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,288 | $9.70 | $12,493.60 |
DisclosureSEC source: 0000882796-26-000057 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,747 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000045 · form4.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000045 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,459 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,262 | $8.91 | $11,244.42 |
DisclosureSEC source: 0000882796-26-000025 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,165 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 21:12 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 71,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-003835 · ownership.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2026. F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2026. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 21:12 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 71,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-26-003835 · ownership.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,226,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:23 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 41,073 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000950103-26-003684 · dp243213_4-frank.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,073 Underlying: Common Stock · 41,073 shares Expires 2036-03-10 Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:23 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 35,612 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-003684 · dp243213_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,612 Underlying: Common Stock · 35,612 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 10, 2027. F3 · derivative.expiration_date: The RSUs vest in full on March 10, 2027. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:23 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 14,245 | $3.51 | $49,999.95 |
DisclosureSEC source: 0000950103-26-003684 · dp243213_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,552 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,285 | $8.75 | $11,243.75 |
DisclosureSEC source: 0000882796-26-000007 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,903 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,566 | $7.18 | $11,243.88 |
DisclosureSEC source: 0000882796-25-000021 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,618 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,353 | $8.31 | $11,243.43 |
DisclosureSEC source: 0000882796-25-000005 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,052 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003911 · ownership.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003911 · ownership.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,699 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 333 | $10.75 | $3,579.75 |
DisclosureSEC source: 0001127602-25-016419 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,199 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $3,585. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 4,079 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001127602-25-013478 · form4.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,079 Underlying: Common Stock · 4,079 shares Expires 2035-05-02 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. F3 · derivative.exercise_date: The option grant vests 1/36 per month over a 3-year period measured from the date of grant. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013478 · form4.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:28 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 87,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-003515 · dp226398_4-frank.xml · derivative · entry 4 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,412 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F4 · derivative.exercise_date: The RSUs vested in full on March 14, 2025. F4 · derivative.expiration_date: The RSUs vested in full on March 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:28 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 87,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-25-003515 · dp226398_4-frank.xml · nonDerivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,140,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 22:28 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 83,517 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0000950103-25-003515 · dp226398_4-frank.xml · derivative · entry 5 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,517 Underlying: Common Stock · 83,517 shares Expires 2035-03-13 Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 22:28 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 71,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-003515 · dp226398_4-frank.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,839 Underlying: Common Stock · 71,839 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 13, 2026. F3 · derivative.expiration_date: The RSUs vest in full on March 13, 2026. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 22:28 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 28,735 | $1.74 | $49,998.90 |
DisclosureSEC source: 0000950103-25-003515 · dp226398_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052,895 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:09 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 101,626 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950103-24-003949 · dp208512_4-frank.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,626 Underlying: Common Stock · 101,626 shares Expires 2034-03-14 Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:09 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 87,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-003949 · dp208512_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,412 Underlying: Common Stock · 87,412 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 14, 2025. F3 · derivative.expiration_date: The RSUs vest in full on March 14, 2025. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:09 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 34,965 | $1.43 | $49,999.95 |
DisclosureSEC source: 0000950103-24-003949 · dp208512_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,160 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 23:55 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 106,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-003748 · dp208304_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 9, 2024. F2 · derivative.expiration_date: The RSUs vested in full on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 23:55 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 106,837 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-24-003748 · dp208304_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 989,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:18 UTC | PRECIGEN, INC. PGEN · Entity 4356 | PurchaseCommon Stock | 400,000 | $1.72 | $688,000.00 |
DisclosureSEC source: 0000950103-23-012088 · dp198547_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882,358 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.48 to $1.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 21:12 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 125,489 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000950103-23-004014 · dp190527_4-frank.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,489 Underlying: Common Stock · 125,489 shares Expires 2033-03-09 Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 21:12 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 106,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-004014 · dp190527_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,837 Underlying: Common Stock · 106,837 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 9, 2024. F3 · derivative.expiration_date: The RSUs vest in full on March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 21:12 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 42,735 | $1.17 | $49,999.95 |
DisclosureSEC source: 0000950103-23-004014 · dp190527_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,358 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:10 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 61,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-003030 · dp189560_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on February 22, 2023. F2 · derivative.expiration_date: The RSUs vested in full on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:10 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 61,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-003030 · dp189560_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 21:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 16,212 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-005410 · dp170038_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 25, 2022. F2 · derivative.expiration_date: The RSUs vested in full on March 25, 2022. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 21:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 16,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-22-005410 · dp170038_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:45 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 83,189 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0000950103-22-003219 · dp167777_4-frank.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,189 Underlying: Common Stock · 83,189 shares Expires 2032-02-22 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:45 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 61,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-003219 · dp167777_4-frank.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 Underlying: Common Stock · 61,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on February 22, 2023. F3 · derivative.expiration_date: The RSUs vest in full on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:45 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 24,630 | $2.03 | $49,998.90 |
DisclosureSEC source: 0000950103-22-003219 · dp167777_4-frank.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,835 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 23:44 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 22,107 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001123292-21-000563 · edgar.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,107 Underlying: Common Stock · 22,107 shares Expires 2031-03-25 Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 23:44 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 16,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000563 · edgar.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,212 Underlying: Common Stock · 16,212 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 25, 2022. F3 · derivative.expiration_date: The restricted stock units vest in full on March 25, 2022. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 23:44 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 6,485 | $7.71 | $49,999.35 |
DisclosureSEC source: 0001123292-21-000563 · edgar.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,205 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 62,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000490 · edgar.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2021. F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2021. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 62,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-21-000490 · edgar.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:02 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 2,968 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0001123292-21-000415 · edgar.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,968 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was immediately exercisable. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:02 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 2,968 | $5.69 | $16,887.92 |
DisclosureSEC source: 0001123292-21-000415 · edgar.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 6, 2020 20:22 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 2,968 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001123292-20-000965 · edgar.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,968 shares Expires 2020-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was immediately exercisable. Read SEC document |
| June 30, 2020 Filed Jul 6, 2020 20:22 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 2,968 | $3.17 | $9,408.56 |
DisclosureSEC source: 0001123292-20-000965 · edgar.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 22:30 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 96,324 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001123292-20-000566 · edgar.xml · derivative · entry 3 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,324 Underlying: Common Stock · 96,324 shares Expires 2030-03-13 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 22:30 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 62,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000566 · edgar.xml · derivative · entry 2 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 Underlying: Common Stock · 62,189 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 13, 2021. F3 · derivative.expiration_date: The restricted stock units vest in full on March 13, 2021. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 22:30 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 24,875 | $2.01 | $49,998.75 |
DisclosureSEC source: 0001123292-20-000566 · edgar.xml · nonDerivative · entry 1 Frank Steven · CIK 0001583886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,595 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $50,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.